GlassScriptPhysician profile
Michael F Morrow
NPI 1922027515
$4,252.23
in general payments reported to CMS, 2019-2025
30 companies · $610 in 2025
The $610 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $356 · 2021: $393 · 2022: $716 · 2023: $675 · 2024: $901 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,085.17 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $569.88 | 2021-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $483.69 | 2019-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $411.90 | 2021-2024 | Symplicity G3, Corevalve Evolut R |
| Novartis Pharmaceuticals Corporation | $372.68 | 2019-2025 | |
| Pfizer INC. | $288.41 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $268.93 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $252.31 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $247.77 | 2019-2024 | Xarelto |
| Amgen INC. | $196.43 | 2019-2024 | Repatha |
| Astrazeneca Pharmaceuticals LP | $187.16 | 2019-2024 | Farxiga |
| Astellas Pharma US INC | $136.36 | 2021-2023 | |
| Abbott Laboratories | $121.63 | 2023-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Ensite |
| Kestra Medical Technology Services, INC. | $87.44 | 2025 | Assure Wcd |
| Philips North America LLC | $79.93 | 2022-2023 | |
| Boston Scientific Corporation | $75.30 | 2019-2024 | Watchman Flx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $71.02 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $69.66 | 2019-2022 | |
| Abiomed | $54.77 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.40 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $32.42 | 2024 | |
| Ge Healthcare | $29.97 | 2020-2022 | |
| Shockwave Medical, INC | $25.78 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Siemens Medical Solutions USA, INC. | $25.16 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $22.67 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.19 | 2025 | Jardiance |
| Inspire Medical Systems, INC. | $17.49 | 2025 | Inspire |
| Alnylam Pharmaceuticals INC. | $16.06 | 2022 | |
| Chiesi USA, INC. | $14.73 | 2021 | |
| Cardiovascular Systems INC. | $13.98 | 2019 | |
| Cvrx, INC. | $6.11 | 2023 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.